Beike is only using adult stem cells (also called somatic stem cells) in its treatment protocols and does not provide embryonic stem cells. It is important to remember that while embryonic stem cells may have more regenerative potential, those may also bring serious medical complications. At Beike Biotechnology, our treatment protocols do not compromise on safety and our adult stem cells have been used effectively for more than 31,500 patients with no serious adverse reaction reported. Learn more about adults stem cells.
The adult stem cells provided in our treatment protocols come from two distinct sources: umbilical cord tissue and umbilical cord blood. This allow us to provide our patients with Umbilical Cord Blood Stem Cells (UCBSC) and Umbilical Cord Mesenchymal Stem Cells (UCMSC) separately or in combination depending on each patient’s specific condition and need. Umbilical cord derived stem cells do not draw any concern from the scientific community and have been proven effective for a wide range of conditions.
Umbilical Cord Blood-Derived Stem Cells (UCBSC)
For a wide range of neurological conditions such as neurodegenerative diseases, brain injuries, visual impairments, motor neuron diseases, muscular dystrophies and hearing loss, Beike recommends treatment using umbilical cord blood stem cells (UCBSC). Our umbilical cord blood stem cells consist of several subsets of stem cells including Hematopoietic Stem Cells (HSC), Endothelial Progenitor Cells (EPC), Mesenchymal … Read more
Umbilical Cord-Derived Mesenchymal Stem Cells (UCMSC)
Based upon research publications and experience, Beike protocols also utilize umbilical cord mesenchymal stem cells (UCMSC) for appropriate conditions autoimmune and inflammatory diseases. These injections contain a higher percentage of mesenchymal stem cells than the umbilical cord blood stem cell injections and closely resemble the makeup of stem cells present in patient’s’ own bone marrow.